Get started
Author

Shir‐Jing Ho

Observed names: S. Ho, S.-J. Ho, S.‐J. HO, S.‐J. Ho, Shir Jing Ho, Shir-Jing Ho
ORCID: 0000-0002-5368-8975
Observed ORCID: 0000-0002-5368-8975
OpenAlex ID: A5077705697
A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)
2015 · Philip Young-Ill Choi, Fernando Roncolato, et al. · Blood · 71
Autoimmune thrombocytopenia
2005 · B.H. CHONG, S.‐J. HO · Journal of Thrombosis and Haemostasis · 64
PDF
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14
2016 · Mark Hertzberg, Maher K. Gandhi, et al. · Haematologica · 58
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience
2020 · Katharine L. Lewis, Collin K. Chin, et al. · British Journal of Haematology · 51
PDF
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
2023 · Stephen Opat, Alessandra Tedeschi, et al. · Blood Advances · 46
PDF
Platelet function testing in uraemic patients
2008 · Shir-Jing Ho, Rosalie Gemmell, et al. · Hematology · 46
PDF
Ximelagatran, direct thrombin inhibitor, oral anticoagulants, thromboprophylaxis
2006 · Shir-Jing Ho, Tim A Brighton · Vascular Health and Risk Management · 45
PDF
Assessment of immunological anti‐platelet factor 4 antibodies for vaccine‐induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients
2022 · Emmanuel J. Favaloro, Joanne Clifford, et al. · Journal of Thrombosis and Haemostasis · 30
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
2023 · Maciej Tatarczuch, Mark Waltham, et al. · Blood Advances · 23
Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)
2016 · Melita Kenealy, Nigel Patton, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 15
Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.
2020 · Jonathan L. Kaufman, Rachid C. Baz, et al. · Journal of Clinical Oncology · 13
Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study
2023 · Nizar J Bahlis, Hang Quach, et al. · Blood · 12
Crystalglobulinemia in Multiple Myeloma: A Rare Case Report of Survival and Renal Recovery
2020 · Angela Chou, Christopher Long, et al. · Canadian Journal of Kidney Health and Disease · 11
First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma
2019 · Nizar Bahlis, Rachid Baz, et al. · Blood · 10
Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity
2018 · Stephen B Ting, Chin Hin Ng, et al. · Blood · 8
Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)
2015 · Mark S Hertzberg, Maher K Gandhi, et al. · Blood · 8
Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial
2022 · Stephen Opat, Alessandra Tedeschi, et al. · Blood · 7
A retrospective validation of ROTEM algorithms for detecting hyperfibrinolysis demonstrates poor agreement for prediction of in-hospital mortality and transfusion requirement in a general, non-cardiac, surgical population
2023 · Leon Rosebery, Matthew Miller, et al. · Thrombosis Research · 6
Sequential high‐dose methotrexate and cytarabine administration improves outcomes in real‐world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance
2024 · Maciej Tatarczuch, Katharine Louise Lewis, et al. · eJHaem · 5
An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
2022 · Jonathan L. Kaufman, Hang Quach, et al. · Blood · 5
Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
2021 · Jonathan L. Kaufman, Hang Quach, et al. · Blood · 5
A partial nucleated differential cell count of the bone marrow aspirate that is independent of peripheral blood dilution
2007 · S.‐H. LEE, S.‐J. HO, et al. · International Journal of Laboratory Hematology · 4
Outcomes for Patients with Primary or Secondary Central System Lymphoma Treated with Ibrutinib: A Multicentre Retrospective Analysis
2019 · Katharine L Lewis, Kate Manos, et al. · Blood · 3
Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma
2022 · Christa Ellen Nath, Andrew Grigg, et al. · European Journal of Clinical Pharmacology · 2
PDF
The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).
2009 · Melita K Kenealy, John F Seymour, et al. · Blood · 2
Works count: 42
Citation count: 555
H-index: 12
I10-index: 14
Year
Topic
Type